Does prasugrel improve safety compared to clopidogrel in patients undergoing percutaneous coronary intervention?
In a phase 2 study, prasugrel demonstrated low rates of bleeding comparable to clopidogrel when administered at the time of PCI, supporting further phase 3 evaluation.
In this phase 2 study, which was designed to assess safety when administered at the time of percutaneous coronary intervention, prasugrel and clopidogrel both resulted in low rates of bleeding. The results of this trial serve as a foundation for the large phase 3 clinical trial designed to assess both efficacy and safety.
Wiviott et al. (Tue,) studied this question.